Defining the role of pharmacology in the emerging world of translational research.

[1]  A. Singleton,et al.  Genomewide association studies and human disease. , 2009, The New England journal of medicine.

[2]  B. Aggarwal,et al.  Models for prevention and treatment of cancer: problems vs promises. , 2009, Biochemical pharmacology.

[3]  Walter H. Moos,et al.  Nonprofit organizations and pharmaceutical research and development , 2009 .

[4]  Irving Kirsch,et al.  The Emperor's New Drugs: Exploding the Antidepressant Myth , 2009 .

[5]  S. Javadov,et al.  Mitochondrial Permeability Transition Pore Opening as a Promising Therapeutic Target in Cardiac Diseases , 2009, Journal of Pharmacology and Experimental Therapeutics.

[6]  Peter B. Dervan,et al.  Allosteric modulation of DNA by small molecules , 2009, Proceedings of the National Academy of Sciences.

[7]  M. Carmo-Fonseca,et al.  The spliceosome: a self-organized macromolecular machine in the nucleus? , 2009, Trends in cell biology.

[8]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[9]  Garret A. FitzGerald,et al.  Moving clinical research in academic medical centres up the value chain , 2009, Nature Reviews Drug Discovery.

[10]  F. Holsboer,et al.  Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects , 2009, Science.

[11]  T. Willson,et al.  Open access chemical and clinical probes to support drug discovery. , 2009, Nature chemical biology.

[12]  Martin Wehling,et al.  Assessing the translatability of drug projects: what needs to be scored to predict success? , 2009, Nature Reviews Drug Discovery.

[13]  Michael Costigan,et al.  Neuropathic pain: a maladaptive response of the nervous system to damage. , 2009, Annual review of neuroscience.

[14]  R. Morimoto,et al.  Biological and chemical approaches to diseases of proteostasis deficiency. , 2009, Annual review of biochemistry.

[15]  John Dixon,et al.  Vertical disintegration: a strategy for pharmaceutical businesses in 2009? , 2009, Nature Reviews Drug Discovery.

[16]  Larry Rubinstein,et al.  Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Patricia M. LoRusso,et al.  Phase 0 clinical trials: an answer to drug development stagnation? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Girardin,et al.  Unleashing the therapeutic potential of NOD-like receptors , 2009, Nature Reviews Drug Discovery.

[19]  Bradley N Gaynes,et al.  Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. , 2009, The American journal of psychiatry.

[20]  M. Williams,et al.  Challenges in the Search for Drugs to Treat Central Nervous System Disorders , 2009, Journal of Pharmacology and Experimental Therapeutics.

[21]  Thomas G Schulze,et al.  Genetic predictors of response to antidepressants in the GENDEP project , 2009, The Pharmacogenomics Journal.

[22]  M. Komatsu,et al.  Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy , 2009, Aging.

[23]  J. Prehn,et al.  Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. , 2009, Biochimica et biophysica acta.

[24]  Edward J. Mills,et al.  Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. , 2008, Journal of the American College of Cardiology.

[25]  John L. LaMattina,et al.  Book Review: Drug Truths: Dispelling the Myths About Pharma R&D , 2008 .

[26]  J. Coyle.  Science and Psychiatry: Groundbreaking Discoveries in Molecular Neuroscience , 2008 .

[27]  E. Gardner.  Use of animal models to develop antiaddiction medications , 2008, Current psychiatry reports.

[28]  Andrew S.C. Rice,et al.  Animal models and the prediction of efficacy in clinical trials of analgesic drugs: A critical appraisal and call for uniform reporting standards , 2008, PAIN.

[29]  S. Green.  Animal research: raise standards to protect patients. , 2008, Nature.

[30]  E. Hayden.  Cancer complexity slows quest for cure , 2008, Nature.

[31]  S. Ramsey,et al.  Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology. , 2008, The oncologist.

[32]  Jocelyn Kaiser,et al.  Industrial-Style Screening Meets Academic Biology , 2008, Science.

[33]  D. Wallace,et al.  Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. , 2008, Arthritis and rheumatism.

[34]  P Jeffrey Conn,et al.  Opportunities and Challenges of Psychiatric Drug Discovery: Roles for Scientists in Academic, Industry, and Government Settings , 2008, Neuropsychopharmacology.

[35]  M. Day,et al.  Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic. , 2008, Current opinion in investigational drugs.

[36]  R. Medzhitov.  Origin and physiological roles of inflammation , 2008, Nature.

[37]  J. Götz,et al.  Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.

[38]  C. Woolf.  Novel analgesic development: from target to patient or patient to target? , 2008, Current opinion in investigational drugs.

[39]  J. Piette,et al.  Fifty years of Biochemical Pharmacology: the discipline and the journal. , 2008, Biochemical pharmacology.

[40]  G. FitzGerald.  Drugs, Industry, and Academia , 2008, Science.

[41]  Martin Wehling,et al.  Translational medicine: science or wishful thinking? , 2008, Journal of Translational Medicine.

[42]  J. Maienschein,et al.  The Ethos and Ethics of Translational Research , 2008, The American journal of bioethics : AJOB.

[43]  Jill U. Adams.  Building the bridge from bench to bedside , 2008, Nature Reviews Drug Discovery.

[44]  K. Thiam,et al.  Use of genetically modified rat models for translational medicine. , 2008, Drug discovery today.

[45]  M. Caterina.  On the thermoregulatory perils of TRPV1 antagonism , 2008, PAIN.

[46]  Larry Rubinstein,et al.  Phase 0 Clinical Trials: Conceptions and Misconceptions , 2008, Cancer journal.

[47]  R. Copeland,et al.  Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.

[48]  L. Leventhal,et al.  Predictive validity of animal pain models? A comparison of the pharmacokinetic–pharmacodynamic relationship for pain drugs in rats and humans , 2008, Neuropharmacology.

[49]  R. Rosenthal,et al.  Antidepressants and suicide , 2008, British medical journal.

[50]  P. Blier.  Do antidepressants really work? , 2008, Journal of psychiatry & neuroscience : JPN.

[51]  M. Chesselet,et al.  Animal models of Parkinson’s disease progression , 2008, Acta Neuropathologica.

[52]  I. Kola,et al.  The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.

[53]  Blair T. Johnson,et al.  Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.

[54]  Michael Williams,et al.  Emerging opportunities for antipsychotic drug discovery in the postgenomic era. , 2008, Journal of medicinal chemistry.

[55]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[56]  S. Woolf.  The meaning of translational research and why it matters. , 2008, JAMA.

[57]  S. Steinberg,et al.  Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. , 2007, Molecular interventions.

[58]  J. L. R. Martin,et al.  Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials , 2007, Journal of psychopharmacology.

[59]  S. Kakkar,et al.  What pharma wants. , 2007, Nature biotechnology.

[60]  H. Fujiki,et al.  Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. , 2007, Cardiovascular drug reviews.

[61]  D. Hackam,et al.  Translating animal research into clinical benefit , 2007, BMJ : British Medical Journal.

[62]  Meindert Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.

[63]  P. Honig.  The value and future of clinical pharmacology , 2007, Clinical pharmacology and therapeutics.

[64]  G. FitzGerald.  Clinical pharmacology or translational medicine and therapeutics: reinvent or rebrand and expand? , 2007, Clinical pharmacology and therapeutics.

[65]  D. Calhoun,et al.  Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide , 2007, Journal of hypertension.

[66]  P. Sandercock,et al.  Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.

[67]  Michael Williams,et al.  Overview of Drug Discovery and Development , 2006, Current protocols in pharmacology.

[68]  Pedro Cuatrecasas,et al.  Drug discovery in jeopardy. , 2006, The Journal of clinical investigation.

[69]  D. Redelmeier,et al.  Translation of research evidence from animals to humans. , 2006, JAMA.

[70]  Sa L. Chiang.  Chemical Genetics: Use of High‐throughput Screening to Identify Small‐molecule Modulators of Proteins Involved in Cellular Pathways with the Aim of Uncovering Protein Function , 2006 .

[71]  John Comley,et al.  Tools and Technologies that Facilitate Automated Screening , 2006 .

[72]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2006, Nature Reviews Drug Discovery.

[73]  A. Carnero,et al.  High throughput screening in drug discovery , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[74]  E. Levin,et al.  Animal Models of Cognitive Impairment , 2006 .

[75]  Mike Collis.  Integrative pharmacology and drug discovery — is the tide finally turning? , 2006, Nature Reviews Drug Discovery.

[76]  A. Marks.  Rescuing the NIH before it is too late. , 2006, The Journal of clinical investigation.

[77]  G. Donnan,et al.  1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.

[78]  H. Rang.  The receptor concept: pharmacology's big idea , 2006, British journal of pharmacology.

[79]  Michael Williams,et al.  Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? , 2005, Biochemical pharmacology.

[80]  J. Greef,et al.  Rescuing drug discovery: in vivo systems pathology and systems pharmacology , 2005, Nature Reviews Drug Discovery.

[81]  C. Martell,et al.  The Myth of Depression as Disease: Limitations and Alternatives to Drug Treatment , 2005 .

[82]  G. FitzGerald.  Anticipating change in drug development: the emerging era of translational medicine and therapeutics , 2005, Nature Reviews Drug Discovery.

[83]  J. Changeux,et al.  Nicotinic Acetylcholine Receptors: From Molecular Biology to Cognition , 2005 .

[84]  D. Wong,et al.  The Discovery of Fluoxetine Hydrochloride (Prozac) , 2005, Nature Reviews Drug Discovery.

[85]  J. Ioannidis.  Why Most Published Research Findings Are False , 2005, PLoS medicine.

[86]  J. Ioannidis.  Contradicted and initially stronger effects in highly cited clinical research. , 2005, JAMA.

[87]  Walter Sneader,et al.  Drug Discovery (The History) , 2005 .

[88]  Karla K Kopec,et al.  Target identification and validation in drug discovery: the role of proteomics. , 2005, Biochemical pharmacology.

[89]  John Harris,et al.  Scientific research is a moral duty , 2005, Journal of Medical Ethics.

[90]  C. Cerni,et al.  Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. , 2005, Mutation research.

[91]  N. Volkow,et al.  Drug addiction: the neurobiology of behaviour gone awry , 2004, Nature Reviews Neuroscience.

[92]  E. Freire,et al.  Isothermal titration calorimetry: controlling binding forces in lead optimization. , 2004, Drug discovery today. Technologies.

[93]  T. Insel,et al.  NIH Molecular Libraries Initiative , 2004, Science.

[94]  E. Lander,et al.  Finishing the euchromatic sequence of the human genome , 2004 .

[95]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[96]  R. Lefkowitz.  Historical review: a brief history and personal retrospective of seven-transmembrane receptors. , 2004, Trends in pharmacological sciences.

[97]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[98]  S. Kurumiya,et al.  Antianxiety and antidepressant‐like effects of AC‐5216, a novel mitochondrial benzodiazepine receptor ligand , 2004, British journal of pharmacology.

[99]  Soldano Ferrone,et al.  Lost in Translation: Obstacles to Translational Medicine , 2004, Journal of Translational Medicine.

[100]  Gunnar Antoni,et al.  Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant , 2004, Biological Psychiatry.

[101]  Gary W. Caldwell,et al.  Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data? , 2004, European Journal of Drug Metabolism and Pharmacokinetics.

[102]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[103]  P. Preusch.  Integrative and organ systems pharmacology: a new initiative from the National Institute of General Medical Sciences. , 2004, Molecular interventions.

[104]  K. Jarnagin.  Receptor Binding in Drug Discovery , 2004 .

[105]  Susan M Abdel-Rahman,et al.  The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. , 2004, Annual review of pharmacology and toxicology.

[106]  Terrence P. Kenakin,et al.  A Pharmacology Primer: Theory, Application and Methods , 2004 .

[107]  G. Duyk.  Attrition and Translation , 2003, Science.

[108]  E. Zerhouni.  The NIH Roadmap , 2003, Science.

[109]  H. Kubinyi.  Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[110]  F. Collins,et al.  A vision for the future of genomics research , 2003, Nature.

[111]  Stephen B. Johnson,et al.  Central challenges facing the national clinical research enterprise. , 2003, JAMA.

[112]  David F. Horrobin,et al.  Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.

[113]  A. Maehle,et al.  The emergence of the drug receptor theory , 2002, Nature Reviews Drug Discovery.

[114]  I. Kirsch,et al.  The Emperor's New Drugs: An Analysis of Antidepressant Medication Data Submitted to the U.S. Food and Drug Administration , 2002 .

[115]  D. Pisetsky,et al.  DNA microarrays: boundless technology or bound by technology? Guidelines for studies using microarray technology. , 2002, Arthritis and rheumatism.

[116]  John Hodgson,et al.  ADMET—turning chemicals into drugs , 2001, Nature Biotechnology.

[117]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[118]  A. Fox,et al.  NK1 receptor antagonists--are they really without effect in the pain clinic? , 2000, Trends in pharmacological sciences.

[119]  H. Bu,et al.  High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites. , 2000, Rapid communications in mass spectrometry : RCM.

[120]  T. Ørntoft,et al.  Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics , 2000, FEBS letters.

[121]  R Hill,et al.  NK1 (substance P) receptor antagonists--why are they not analgesic in humans? , 2000, Trends in pharmacological sciences.

[122]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[123]  D. Donnelly-roberts,et al.  Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. , 1998, Science.

[124]  T. Kenakin.  The classification of seven transmembrane receptors in recombinant expression systems. , 1996, Pharmacological reviews.

[125]  M. Wolff,et al.  BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY , 1996 .

[126]  Walter H. Moos,et al.  Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies , 1995 .

[127]  J. Pc,et al.  The essential role of integrative biomedical sciences in protecting and contributing to the health and well-being of our nation. , 1994 .

[128]  John Maddox,et al.  Is molecular biology yet a science? , 1992, Nature.

[129]  J. Maddox.  Crystals from first principles , 1988, Nature.

[130]  M. Goodall,et al.  The acetylcholine receptor. Isolation of a brain nicotinic receptor and its preliminary characterization in lipid bilayer membranes. , 1974, Biochimica et biophysica acta.

[131]  A. Eldefrawi,et al.  Characterization and partial purification of the acetylcholine receptor from Torpedo electroplax. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[132]  A. Hui,et al.  The development and pharmacology of proteasome inhibitors for the management and treatment of cancer. , 2009, Advances in pharmacology.

[133]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[134]  Michael Williams.  Progress in Alzheimer's disease drug discovery: an update. , 2009, Current opinion in investigational drugs.

[135]  K. Kashfi.  Anti-inflammatory agents as cancer therapeutics. , 2009, Advances in pharmacology.

[136]  L. Brady,et al.  NIMH Initiatives to Facilitate Collaborations Among Industry, Academia, and Government for the Discovery and Clinical Testing of Novel Models and Drugs for Psychiatric Disorders , 2009, Neuropsychopharmacology.

[137]  R. Hampson,et al.  Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease , 2008 .

[138]  C. Heidbreder.  Impulse and Reward Deficit Disorders: Drug Discovery and Development , 2008 .

[139]  F. Chast.  A History of Drug Discovery , 2008 .

[140]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[141]  Michael Williams.  Perseverance furthers? The role of the drug hunter in the postgenomic era. , 2008, Current opinion in investigational drugs.

[142]  M. Millan.  The Discovery and Development of Pharmacotherapy for Psychiatric Disorders: A Critical Survey of Animal and Translational Models and Perspectives for Their Improvement , 2008 .

[143]  D. Shealy,et al.  Anti-TNF antibodies: lessons from the past, roadmap for the future. , 2008, Handbook of experimental pharmacology.

[144]  F. Martinon,et al.  Inflammatory caspases and inflammasomes: master switches of inflammation , 2007, Cell Death and Differentiation.

[145]  D. J. Triggle,et al.  Comprehensive medicinal chemistry II , 2006 .

[146]  J. Lieberman,et al.  THE SILENT REVOLUTION : RNA Interference as Basic Biology , Research Tool , and Therapeutic , 2010 .

[147]  Michael Williams.  A return to the fundamentals of drug discovery? , 2004, Current opinion in investigational drugs.

[148]  George M. Milne,et al.  Chapter 35. Pharmaceutical productivity — the imperative for new paradigms , 2003 .

[149]  Inger Sandlie,et al.  Therapeutic antibodies for human diseases at the dawn of the twenty-first century , 2003, Nature Reviews Drug Discovery.

[150]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[151]  Peter Gwynne,et al.  Drug Discovery: 5 , 2002 .

[152]  M. Parnham,et al.  Pharmacological methods, receptors & chemotherapy , 1986 .

[153]  H. Haas,et al.  [The placebo problem]. , 1959, Fortschritte der Arzneimittelforschung. Progress in drug research. Progres des recherches pharmaceutiques.